Biomarkers of PRP mutation, misfolding and deficiency

This study addresses a critical practical question for prion disease therapeutics: how rapidly is cellular prion protein (PrP) turned over in vivo and how might PrP turnover constrain the time to therapeutic effect of PrP-lowering interventions? The study frames the problem by noting that current and pipeline therapies lower ongoing PrP production, but leave pre-existing PrP to be cleared according to its native half-life. The authors hypothesized that PrP half-life could be a rate-limiting determinant of how quickly PrP-lowering drugs manifest benefit, potentially explaining why late treatment in animal models is less effective than early treatment. To test this hypothesis, the team used complementary experimental approaches. They fed animals isotopically labeled chow and applied targeted mass spectrometry to track incorporation of label into PrP peptides over time, enabling direct estimation of PrP turnover.

They also administered antisense oligonucleotide (ASO) treatment to lower PrP production and performed timed measurements of PrP to observe the decline driven by reduced synthesis. Using these methods, the investigators estimate a PrP half-life in brain on the order of 5–6 days. They further report that PrP turnover is not substantially altered by overexpression or underexpression of PrP, and that mouse PrP and human PrP show similar turnover rates when measured in wild-type or humanized knock-in mice. Beyond the central nervous system, the study examines peripheral tissues and cerebrospinal fluid (CSF). CSF PrP appears to mirror brain PrP in real time in rats, suggesting CSF PrP may serve as a proximate biomarker of brain PrP dynamics. Among peripheral organs, colon emerged as a tissue in which PrP is relatively readily quantifiable and where PrP appears to have a shorter half-life compared to brain. The authors support tissue selection for peripheral quantification with RNA expression data (GTEx) and biochemical assays including Western blot and ELISA adapted for PrP detection in various organs.

These findings have direct implications for the design of both preclinical and clinical studies of PrP-lowering drugs. Knowing a brain PrP half-life of roughly one week informs expectations for the lag time between reduction in PrP synthesis and observable decreases in total PrP protein, whether measured in tissue or mirrored in CSF. Shorter peripheral half-lives in tissues like colon may offer alternative or complementary sampling sites for monitoring pharmacodynamic effects. The study thus provides empirically derived parameters that can guide timing of outcome measurements, interpretation of biomarker trajectories, and planning of dosing regimens in development programs targeting PrP. By combining isotopic labeling, targeted proteomics, and ASO-mediated perturbation, the work supplies actionable quantitative data on PrP kinetics that can inform translational strategies for PrP-lowering therapeutics.